会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • NON-IRRITATING SOLVENT-BORNE POLYMERIC COATINGS FOR APPLICATION TO THE SKIN
    • 非刺激性溶剂型聚合物涂层用于皮肤
    • WO2007025261A3
    • 2007-10-04
    • PCT/US2006033589
    • 2006-08-28
    • PERLMAN DANIEL
    • PERLMAN DANIEL
    • A61K31/717A61K9/70
    • A61K31/717A61K9/70A61L26/0023C08L1/00
    • A method and composition for reducing or eliminating stinging that may accompany application of topical solution of a skin-compatible polymeric material to a skin wound, abrasion, burn or other skin injury. The topical solution may contain one or more skin-irritating chemicals, such as diethyl ether, ethanol, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone and combinations thereof. The method includes: (i) providing a composition that contains between 1% and 10% by weight of the skin-compatible polymeric material dissolved in a liquid medium suitable for human topical use in which the liquid medium includes less than 20% combined weight of skin-irritating chemicals, and at least 45% combined weight of at least one volatile solvent and/or volatile co-solvent, in which the molecules constituting this 45% combined weight portion of the liquid medium contain at least 5 carbon atoms, and the liquid medium has an initial boiling point at 1 atmosphere of greater than 35°C and less than 150°C, and causes little or no stinging when applied to a skin injury, and (ii) applying the composition to the skin of a patient at the site of the skin injury.
    • 用于减少或消除可能伴随皮肤相容性聚合物材料的局部溶液应用于皮肤伤口,磨损,灼伤或其他皮肤损伤的刺痛的方法和组合物。 局部溶液可含有一种或多种皮肤刺激性化学物质,如乙醚,乙醇,乙酸乙酯,乙酸甲酯,丙酮,甲乙酮及其组合。 该方法包括:(i)提供一种组合物,其含有溶解在适用于人体局部应用的液体介质中的1重量%至10重量%的所述皮肤相容性聚合物材料,其中所述液体介质包含小于20重量% 刺激皮肤的化学物质和至少45%的组合重量的至少一种挥发性溶剂和/或挥发性共溶剂,其中构成该液体介质的45重量%组合重量部分的分子含有至少5个碳原子,并且 液体培养基在1个大气压下的初始沸点大于35℃且小于150℃,并且当施用于皮肤损伤时引起很少或没有刺痛,和(ii)将所述组合物施用于患者的皮肤上 皮肤损伤的部位。
    • 7. 发明申请
    • BALANCED MYRISTATE- AND LAURATE-CONTAINING EDIBLE OIL
    • 平衡含糖和含莴苣的可食用油
    • WO2011106618A8
    • 2012-09-13
    • PCT/US2011026203
    • 2011-02-25
    • UNIV BRANDEISPERLMAN DANIELHAYES KENNETH C
    • PERLMAN DANIELHAYES KENNETH C
    • A23D7/00A23D9/00A23L1/29A23L1/30
    • A23D7/001A23D7/003A23D9/00A23K20/158A23L33/12A23V2002/00A61K31/20A61K31/201A61K45/06A61K2300/00A23V2250/1882A23V2200/3262A23V2250/186A23V2250/1872
    • Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.
    • 描述了用于增加HDL胆固醇,降低总胆固醇(TC),低密度脂蛋白胆固醇和降低人血浆中LDL / HDL胆固醇比例的营养脂肪或油基组合物。 组合物可以有利地包括至少10%的肉豆蔻酸和/或月桂酸,其中至少3%的所述脂肪酸组合物是肉豆蔻酸,并且至少3%是月桂酸; 在一些情况下,至少1重量%的肉豆蔻酸和/或月桂酸在甘油三酯分子的sn-2位被酯化。 组合物还包括5重量%至40重量%的亚油酸,并且通常还包括至少10重量%的单不饱和脂肪酸和15重量%至55重量%的总饱和脂肪酸。 饱和,单不饱和和多不饱和脂肪酸的重量百分比之和等于100%。 在期望的情况下,组合物基本上不含胆固醇。 还描述了脂肪组合物和饮食,其适于限制血液甘油三酯,总胆固醇,低密度脂蛋白和VLDL的增加,即使在膳食胆固醇的存在下。
    • 8. 发明申请
    • SN-2 MYRISTATE-CONTAINING EDIBLE OIL
    • SN-2含有香料的食用油
    • WO2010027433A3
    • 2010-05-14
    • PCT/US2009004860
    • 2009-08-25
    • UNIV BRANDEISPERLMAN DANIELHAYES KENNETH C
    • PERLMAN DANIELHAYES KENNETH C
    • A23D7/00
    • C11C3/10A23D9/02A23L33/12
    • A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma is described. The composition can advantageously include at least 1 % by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1 :1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free.
    • 描述了用于增加人血浆中HDL胆固醇,降低LDL胆固醇和降低LDL / HDL胆固醇比的营养型油或脂基组合物。 所述组合物可以有利地包含在甘油三酯分子中在sn-2位酯化的至少1重量%的肉豆蔻酸,包含10重量%至40重量%的亚油酸,并且还包含30重量%至65重量%的油酸和 按重量计15%至40%的总饱和脂肪酸。 sn-2肉豆蔻酸与sn-2棕榈酸的比例通常大于1:1,饱和,单不饱和脂肪酸和多不饱和脂肪酸的重量百分比之和等于100%。 在理想的情况下,该组合物基本上不含胆固醇。